Shares of CSL Limited Sponsored ADR (OTCMKTS:CSLLY – Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $59.72, but opened at $57.45. CSL shares last traded at $57.43, with a volume of 1,320 shares.
Wall Street Analyst Weigh In
CSLLY has been the topic of a number of analyst reports. Canaccord Genuity Group raised CSL from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 28th. Zacks Research cut CSL from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 18th. Two analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, CSL currently has an average rating of “Buy”.
Check Out Our Latest Analysis on CSL
CSL Trading Up 1.5%
About CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Read More
- Five stocks we like better than CSL
- P/E Ratio Calculation: How to Assess Stocks
- Rocket Lab’s Sharp Rebound: What’s Behind the Recent Momentum
- How to Calculate Inflation Rate
- Jabil Is Flying Under the Radar—But a 50% Surge May Be Coming
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Qualcomm’s Monster Rally Has a Catch—Can the Stock Keep Climbing?
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
